Approval covers the Tumor Treating Fields (TTFields) delivery technology for concomitant use with gemcitabine and nab-paclitaxel.

Optune Pax, a portable, therapeutic device, delivers TTFields non-invasively through wearable arrays. The alternating electrical feilds target the electrical properties of cancer cells to disrupt processes critical for cancer cell division and survival. This leads to cell death without significantly affecting healthy cells.

Small and lightweight, the device offers a wearable, portable option for continuing normal daily activities. The company designed it for enhanced carrying comfort and usability.